<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04425629</url>
  </required_header>
  <id_info>
    <org_study_id>R10933-10987-COV-2067</org_study_id>
    <nct_id>NCT04425629</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19</brief_title>
  <official_title>A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives are:

      Phase 1

        -  To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo

        -  To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in
           reducing viral shedding of SARS-CoV-2

      Phase 2 • To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in
      reducing viral shedding of SARS-CoV-2

      Phase 3

      • To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Anticipated">November 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1/Phase 2/Phase 3</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with treatment-emergent serious adverse events (SAEs)</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary:
Phase 1
Secondary:
Phase 2, Phase 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with infusion-related reactions</measure>
    <time_frame>Through Day 4</time_frame>
    <description>Primary:
Phase 1
Secondary:
Phase 2, Phase 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with hypersensitivity reactions</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary:
Phase 1
Secondary:
Phase 2, Phase 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-weighted average change from baseline in viral shedding as measured by quantitative reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples</measure>
    <time_frame>Baseline up to Day 22</time_frame>
    <description>Primary:
Phase 1, Phase 2
Secondary:
Phase 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with at least one COVID-19 related medically attended visit</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary:
Phase 3
Secondary:
Phase 1, Phase 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-weighted average change from baseline in viral shedding measured by RT-qPCR in saliva samples</measure>
    <time_frame>Baseline up to Day 22</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-weighted average change from baseline in viral shedding measured by RT-qPCR in nasal swab samples</measure>
    <time_frame>Baseline up to Day 22</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative RT-qPCR in NP swabs with no subsequent positive RT-qPCR</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2, Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in viral shedding as measured by RT-qPCR in NP swabs</measure>
    <time_frame>Baseline up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in viral shedding as measured by RT-qPCR in saliva samples</measure>
    <time_frame>Baseline up to Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in viral shedding as measured by RT-qPCR in nasal swabs</measure>
    <time_frame>Baseline up to Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of RT-qPCR results over time between different sample types (NP, nasal, and saliva)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance of RT-qPCR results over time between different sample types (NP, nasal, and saliva)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Phase 1 Only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-weighted average change from baseline in viral shedding</measure>
    <time_frame>Baseline up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with at least two COVID-19 related medically attended visits</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of COVID-19 related medically-attended visits</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients admitted to a hospital due to COVID-19</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients admitted to an intensive care unit (ICU) due to COVID-19</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2, Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients at least 1 outpatient or telemedicine visit due to COVID-19</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring mechanical ventilation due to COVID-19</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2, Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospitalization due to COVID-19</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2, Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths due to any cause (All-Cause Mortality)</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2, Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of REGN10933 over time</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of REGN10987 over time</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10933</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10987</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Time to Cmax (tmax) for REGN10933</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Time to Cmax (tmax) for REGN10987</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA) to REGN10933</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA) to REGN10987</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1454</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>REGN10933+REGN10987 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>REGN10933+REGN10987 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN10933+REGN10987 combination therapy</intervention_name>
    <description>Administered intravenously (IV) single dose</description>
    <arm_group_label>REGN10933+REGN10987 high dose</arm_group_label>
    <arm_group_label>REGN10933+REGN10987 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV Single Dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Has SARS-CoV-2-positive molecular diagnostic test (by validated SARS-CoV-2 RT-PCR or
             other molecular diagnostic assay, using an appropriate sample such as NP, nasal,
             oropharyngeal [OP], or saliva) ≤72 hours prior to randomization. A historical record
             of positive result from test conducted ≤72 hours prior to randomization is acceptable

          -  Is experiencing ≥1 of the following symptoms at randomization: fever, cough, shortness
             of breath

          -  Has experienced COVID-19 symptoms for &lt;7 days

          -  Has symptoms consistent with COVID-19, as determined by investigator, with onset ≤7
             days before randomization

        Key Exclusion Criteria:

          -  Has been admitted to a hospital prior to randomization, or is hospitalized (inpatient)
             at randomization, due to COVID-19

          -  Has participated, or is participating, in a clinical research study evaluating
             COVID-19 convalescent plasma, monoclonal antibodies (mAbs) against SARS-CoV-2, or
             intravenous immunoglobulin (IVIG) within 3 months or less than 5 half-lives of the
             investigational product (whichever is longer) prior to the screening visit

          -  Has a history of COVID-19 investigational or Emergency Use Authorization
             (EUA)-approved treatments in the past 30 days or less than 5 half-lives of the
             investigational product (whichever is longer) prior to the screening visit. This
             includes, but is not limited to: remdesivir, hydroxychloroquine, tocilizumab,
             sarilumab, and other immunomodulatory agents

          -  Current use of any COVID-19 investigational or EUA-approved treatment

        NOTE: Other Protocol defined Inclusion/Exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010-3014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus disease 2019 (COVID-19)</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2)</keyword>
  <keyword>coronavirus</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

